Clinical Trial

Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is being conducted to evaluate the safety and efficacy of the combination of pemetrexed and zanubrutinib (called induction therapy) followed by zanubrutinib treatment alone (also called maintenance therapy) in people who have relapsed or refractory (RR) primary central nervous system lymphoma (PCNSL) or isolated central nervous system relapse of B cell lymphoma (SCNSL). Assessments include how well people respond to this treatment, whether their disease gets better or worse, and their survival. Safety of this treatment and its side effects also will be assessed.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2022-12-23; most recent amendment 2026-03-02.
Status change: Not Yet Recruiting → Recruiting 2023-10-02
Trial Details
NCT Number NCT05681195
Lead Sponsor Baptist Health South Florida
Collaborators: BeiGene
Conditions Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma, Relapsed Cancer, Refractory Cancer
Enrollment 15 participants
Start Date 2024-04-25
Primary Completion 2028-02 (estimated)
Study Completion 2033-02 (estimated)
Updated on ClinicalTrials.gov 2026-03-03